Work

Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers

Year: 2019

Type: article

Source: Journal of Thoracic Oncology

DOI: 10.1016/j.jtho.2018.12.038

Authors: Morana Vojnic, Daisuke Kubota, Christopher Kurzatkowski, Michael Offin, Ken Suzawa, Ryma Benayed, Adam J. Schoenfeld, Andrew J. Plodkowski, John T. Poirier, Charles M. Rudin, Mark G. Kris, Neal X. Rosen, Helena A. Yu, Gregory J. Riely, Maria E. Arcila, Romel Somwar, Marc Ladanyi

Institutions: Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, GlaxoSmithKline, Ariad Pharmaceuticals, Helsinn, BeiGene, Incyte, Astellas Pharma, National Institutes of Health, Genentech, Chugai Pharmaceutical, Loxo Oncology, National Cancer Institute

Awards: G1229558712, G2684890037, G6516949535, G9000003249, G9000023475, G9000079197, G9000090134, G9000150436, Cancer Center Support Grant

OpenAlex ID: W2919959132

FWCI: 10.04

Cites: 41

Cited by: 104

Related to: 10